Neuren’s Growth Hinges on Acadia’s Sales Force Expansion and European Approval
Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.
- Q2 2025 DAYBUE net sales up 14% year-on-year to US$96.1 million
- Neuren’s Q2 royalty income rises 16% to A$14.7 million
- Record 987 unique patients treated in the US, growing for third consecutive quarter
- Acadia expands DAYBUE sales force by ~30% to boost community penetration
- European marketing approval expected in Q1 2026 with named patient programs underway
Robust Growth in DAYBUE Sales
Neuren Pharmaceuticals has reported a solid quarter with Q2 2025 royalty income reaching A$14.7 million, marking a 16% increase compared to the same period last year. This growth is underpinned by Acadia Pharmaceuticals’ DAYBUE™ (trofinetide) net sales of US$96.1 million, which rose 14% year-on-year and sequentially from Q1 2025. The steady climb reflects a growing patient base and sustained demand for this rare disease therapy.
Expanding Patient Reach and Sales Force
Acadia’s efforts to broaden DAYBUE’s reach are evident in the record number of unique patients receiving shipments in the US, which hit 987 in Q2, up from 954 in the previous quarter. Notably, approximately 75% of new patient referrals now come from community sources rather than specialised Rett syndrome centres, a shift facilitated by a 30% expansion of Acadia’s sales force. This strategic move aims to accelerate growth by tapping into a wider patient population.
Outlook and International Expansion
Acadia has reaffirmed its full-year 2025 US net sales guidance for DAYBUE at US$380-405 million, implying Neuren’s royalty income could reach between A$62 million and A$67 million, assuming stable exchange rates. Beyond the US, preparations for European market entry are advancing, with the marketing application expected to be approved in Q1 2026. Meanwhile, named patient supply programs have been initiated across Europe, Israel, and other regions, laying groundwork for future commercialisation.
Pipeline Progress and Strategic Leadership
While DAYBUE remains the commercial flagship, Neuren continues to develop its second drug candidate, NNZ-2591, targeting multiple neurodevelopmental disorders with encouraging Phase 2 results. The company also benefits from strengthened leadership at Acadia, including the appointment of Allyson McMillian-Youngblood as Senior Vice President of Rare Disease Franchise, signaling a focused commitment to rare disease markets.
Implications for Investors
The consistent growth in royalties and patient numbers, coupled with strategic sales force expansion and international rollout plans, position Neuren well for sustained revenue momentum. However, the full-year royalty outlook hinges on Acadia meeting its sales targets and regulatory approvals proceeding as anticipated, factors investors will watch closely in the coming months.
Bottom Line?
Neuren’s royalty trajectory looks promising, but the next milestones in European approval and sales expansion will be critical to watch.
Questions in the middle?
- Will Acadia’s expanded sales force sustain patient growth beyond Q3 2025?
- How will European regulatory approval impact Neuren’s revenue profile in 2026?
- What progress can be expected from Neuren’s NNZ-2591 clinical development this year?
